AlphAIAlphAI — Financial news for AI agents
tradingview.com$AMGN

Freedom Broker downgrades Amgen to Hold from Buy, raises price target to $470 from $450

Freedom Broker downgraded Amgen to Hold from Buy but raised its price target to $470 from $450, a 4.4% increase. The new target implies a 2.1% upside from Amgen's Nov 6 close of $460.42. Recent analyst price targets for Amgen range from $435 to $530.

Original reporting
tradingview.com
Published Nov 6, 2026, 11:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Freedom Broker downgrades Amgen to Hold from Buy, raises price target to $470 from $450 — source image
Source · tradingview.com
Decision brief

The 30-second read

$AMGNBearishMed
01

Why it matters

The downgrade may trigger short‑term selling pressure, but the raised target could attract value investors.

02

Market read

Analyst downgrade to Hold is a fresh catalyst that could influence AMGN's near‑term price action.

03

What to watch

Potential upcoming clinical data releases could offset the downgrade impact.

Relevance 7/10Novelty 6/10Timing: pre‑market tomorrow

Background

Freedom Broker's rating change is the first public disclosure of this analyst action.

Company-level read

Ticker impact

$AMGNBearishHigh confidence
Context

Freedom Broker downgraded Amgen to Hold and raised its price target to $470 from $450.

Expected impact

likely modest downside as investors digest the downgrade

Evidence & confidence

Downgrade signals reduced confidence; price target increase is insufficient to offset the negative rating.

Market effects

Sector

Biotech sector may see slight pressure as a large‑cap name receives a downgrade.

Regional

U.S. market sentiment could dip marginally in healthcare stocks.

Global

Limited; impact confined to Amgen and peers.

Counterpoint

What could challenge this read

The higher price target suggests upside potential if the downgrade is viewed as a technical adjustment.

Key entities

  • company
    Amgen

    Biopharmaceutical company receiving the downgrade.

  • analyst
    Freedom Broker

    Research firm issuing the downgrade and new price target.

Read at source← All news

StoryFreedom Broker downgrades Amgen to Hold while raising price target to $470

Also covered by

1 outlet

Related articles

$AMGNMed

Freedom Broker downgrades Amgen stock rating on valuation despite raising price target

Freedom Broker downgraded Amgen (AMGN) to Hold from Buy, raising its price target to $470. The move follows strong quarterly results, with revenue and EPS beating expectations. Amgen raised its full-year guidance, and shares are up 44% year-to-date. Analysts cite strong performance but note the stock is near fair value. Other analysts, including UBS and RBC, raised their price targets.

investing.com
$AMGNLow

FDA Approval for AMJEVITA issued to AMGEN INC

The FDA approved a label update for Amgen's AMJEVITA (adalimumab-atto) on 11/05/2026, according to the company. The approval covers the 20 mg/0.4 mL and 40 mg/0.8 mL injectable products, but no new indication was disclosed. This is a routine regulatory update for an already approved product.

quantisnow.com
$AMGNMed

Amgen’s Repatha reduces heart attack risk in real-world study

Amgen's Repatha (evolocumab) reduced heart attack risk by 20% compared to ezetimibe in a real-world study of 544,103 adults with atherosclerotic cardiovascular disease, according to the company. The four-year study tracked patients from 2017 to 2024, with Repatha showing a lower cumulative incidence of heart attacks (5.88% vs. 7.76%). Amgen's chief medical officer highlighted the study's relevance for treatment decisions.

clinicaltrialsarena.com
$AMGNHighAI 8/10

While biotech bets swing on trial data, this dividend payer gained 72% since 2024 By Investing.com RSS CTA

Amgen (AMGN) reported Q3 earnings of $6.45 per share, beating estimates by 12%, with revenue of $10.4B, up 9% YoY. The company's stock has gained 72% since late 2024, driven by strong commercial performance and a robust pipeline. Analysts have mixed views on its valuation, with a forward P/E of 19.9x. Amgen has raised its dividend for 16 consecutive years, yielding 2.2%.

investing.com